Atazanavir/ritonavir
| Combination of | |
|---|---|
| Atazanavir | Protease inhibitor |
| Ritonavir | Protease inhibitor (pharmacokinetic booster) |
| Names | |
| Trade names | Ritovaz |
| Other names | Anzavir-R, ritonavir/atazanavir[1] |
| Clinical data | |
| Routes of use | By mouth[1] |
| Defined daily dose | 0.3 gram[2] |
| Legal | |
| Legal status |
|
Atazanavir/ritonavir (ATV/r) is a fixed-dose combination medication used in the treatment of HIV/AIDS.[1] It combines atazanavir and ritonavir.[1] It may be used instead of lopinavir/ritonavir.[3] It is taken by mouth.[1]
Side effects are generally minimal.[3] They may include abdominal pain, diarrhea, yellowish skin, muscle pains, and headache.[3] Greater care should be taken in people with underlying liver problems.[3] Use in pregnancy appears to be safe.[4] In the combination atazanavir functions as a protease inhibitor and ritonavir functions to increase levels of atazanavir.[3]
The combination was approved for use in India in 2012, and is pending approval in the United States As of 2017[update].[1] It is on the World Health Organization's List of Essential Medicines.[5] The average cost per year is 281 USD in the developing world as of 2012.[3]
Dosage
The defined daily dose is 0.3 gram (by mouth) refers to atazanavir[2]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "Atazanavir/ritonavir - Mylan Laboratories - AdisInsight". adisinsight.springer.com. Archived from the original on 11 December 2017. Retrieved 29 June 2017.
- ↑ 2.0 2.1 "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 12 April 2020. Retrieved 12 September 2020.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 "Atazanavir + ritonavir (Addition) -- Adults". World Health Organization (WHO). Archived from the original on 3 February 2020. Retrieved 29 June 2017.
- ↑ "Atazanavir/Ritonavir in Pregnancy". hivinsite.ucsf.edu. Archived from the original on 29 January 2018. Retrieved 10 December 2017.
- ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
External links
| Identifiers: |
|---|
 | This antiinfective drug article is a stub. You can help MDWiki by expanding it. |
- Pages using duplicate arguments in template calls
- Use dmy dates from February 2020
- Articles with invalid date parameter in template
- Drugs with non-standard legal status
- Chemical articles with unknown parameter in Infobox drug
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- Articles containing potentially dated statements from 2017
- All articles containing potentially dated statements
- World Health Organization essential medicines
- RTT
- All stub articles
- Antiinfective agent stubs